{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T08:08:50Z","timestamp":1748333330738},"reference-count":13,"publisher":"Wiley","issue":"7-8","license":[{"start":{"date-parts":[[2002,10,17]],"date-time":"2002-10-17T00:00:00Z","timestamp":1034812800000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2002,10]]},"abstract":"<jats:p><jats:bold>Summary.\u2003<\/jats:bold>  <jats:italic>In vitro<\/jats:italic> susceptibility to the sordarin derivative GM 237354 and amphotericin B were tested in a total of 190 <jats:italic>Cryptococcus neoformans<\/jats:italic> clinical isolates from different geographical areas of Spain and South American countries. Minimal inhibitory concentrations (MICs) were obtained using the NCCLS reference microbroth dilution method and analysed according the serotypes of <jats:italic>Cr. neoformans<\/jats:italic>. The MICs for amphotericin B were lower than 1.0\u2003<jats:italic>\u03bc<\/jats:italic>g\u2003ml<jats:sup>\u22121<\/jats:sup> (MIC<jats:sub>90%<\/jats:sub> 0.5\u2003<jats:italic>\u03bc<\/jats:italic>g\u2003ml<jats:sup>\u22121<\/jats:sup>, MIC<jats:sub>50%<\/jats:sub> 0.125\u2003<jats:italic>\u03bc<\/jats:italic>g\u2003ml<jats:sup>\u22121<\/jats:sup>) but five isolates showed MICs of 2.0\u2003<jats:italic>\u03bc<\/jats:italic>g\u2003ml<jats:sup>\u22121<\/jats:sup> to GM 237354 (MIC<jats:sub>90%<\/jats:sub> 1.0\u2003<jats:italic>\u03bc<\/jats:italic>g\u2003ml<jats:sup>\u22121<\/jats:sup>, MIC<jats:sub>50%<\/jats:sub> 0.5\u2003<jats:italic>\u03bc<\/jats:italic>g\u2003ml<jats:sup>\u22121<\/jats:sup>). <jats:italic>Cryptococcus neoformans<\/jats:italic> var. <jats:italic>gattii<\/jats:italic> serotype B, was significantly less susceptible than A and AD serotypes (<jats:italic>P<\/jats:italic>=0.047 and <jats:italic>P<\/jats:italic>=0.022, respectively).<\/jats:p>","DOI":"10.1046\/j.1439-0507.2002.00787.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T14:49:31Z","timestamp":1047480571000},"page":"313-316","source":"Crossref","is-referenced-by-count":2,"title":["<i>In vitro<\/i> susceptibility of <i>Cryptococcus neoformans<\/i> serotypes to GM 237354 derivative of the sordarin class"],"prefix":"10.1111","volume":"45","author":[{"given":"J. M.","family":"Torres\u2010Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Morera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Bar\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Al\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,11,5]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1128\/AAC.42.9.2274","article-title":"Sordarins: a new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts","volume":"42","author":"Dom\u00ednguez J. M.","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.39.25041"},{"key":"e_1_2_9_4_2","first-page":"Abstract","volume-title":"Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy.","author":"Mart\u00ednez A.","year":"1997"},{"key":"e_1_2_9_5_2","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1128\/JCM.37.4.1170-1172.1999","article-title":"Serotyping of Cryptococcus neoformans isolates from clinical and environmental sources in Spain","volume":"37","author":"Bar\u00f3 T.","year":"1999","journal-title":"J. Clin. Microbiol."},{"key":"e_1_2_9_6_2","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeasts: Approved Standard. M27\u2010A.","author":"National Committee for Clinical Laboratory Standards.","year":"1997"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.5.645"},{"key":"e_1_2_9_8_2","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1128\/JCM.36.10.2817-2822.1998","article-title":"Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E\u2010Test and National Committee of Clinical Laboratory Standards M27\u2010A methodologies","volume":"36","author":"Lozano\u2010Chiu M.","year":"1998","journal-title":"J. Clin. Microbiol."},{"key":"e_1_2_9_9_2","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1128\/AAC.42.11.2863","article-title":"Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi","volume":"42","author":"Herreros E.","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_2_9_10_2","first-page":"Abstract","volume-title":"Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy.","author":"Stevens D. A.","year":"1997"},{"key":"e_1_2_9_11_2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1128\/JCM.37.3.838-840.1999","article-title":"Cyptococcus neoformans var. grubii: separate variety status for Cryptococcus neoformans serotype A isolates","volume":"37","author":"Franzot S. P.","year":"1999","journal-title":"J. Clin. Microbiol."},{"key":"e_1_2_9_12_2","first-page":"140","article-title":"Caract\u00e8res mycologiques et sensibilit\u00e9 aux antifongiques des souches de Cryptococcus neoformans isolates de patients atteints du SIDA ou d'autres provenances","volume":"2","author":"Gargani G.","year":"1992","journal-title":"J. Mycol. M\u00e9d."},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007376917836"},{"key":"e_1_2_9_14_2","first-page":"185","article-title":"Relationship between the in vitro activity of four antifungal drugs and the serotypes of Cryptococcus neoformans","volume":"11","author":"Bar\u00f3 T.","year":"2001","journal-title":"J. Mycol. M\u00e9d."}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1439-0507.2002.00787.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1439-0507.2002.00787.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T12:31:13Z","timestamp":1693398673000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1439-0507.2002.00787.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":13,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["10.1046\/j.1439-0507.2002.00787.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1439-0507.2002.00787.x","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}